Maria Papaleontiou, MD
Division of Metabolism, Endocrinology and Diabetes; Department of Internal Medicine
North Campus Research Complex 2800 Plymouth Road, Bldg. 16, Rm 453S
Ann Arbor, MI 48019
Manage Your Profile
About
Maria Papaleontiou, MD, is an Associate Professor of Internal Medicine with an appointment in the Division of Metabolism, Endocrinology and Diabetes, and a Research Associate Professor at the Institute of Gerontology, at the University of Michigan. She also serves as the Associate Program Director for the MEND Fellowship. Prior to starting her internal medicine residency at Saint Peter's University Hospital in New Jersey, she spent several years conducting clinical research on aging at Weill Cornell Medical College in New York City. She completed her endocrinology fellowship at the University of Michigan, where she subsequently joined the faculty in 2013. She is a recipient of Fulbright and Howard Hughes Medical Institute scholarships. Her clinical practice focuses on thyroid diseases and thyroid cancer, as well as geriatric endocrinology.
Dr. Papaleontiou is also a health services researcher in the field of thyroidology and aging. Her research focuses on evaluating the risks of thyroid hormone overtreatment and misuse in older adults, understanding the role of providers and patients in thyroid hormone use and misuse and how it relates to patient outcomes in the aging population, as well as the role of age and comorbidity in thyroid cancer decision-making. Her ultimate goal is to develop tools to tailor thyroid disease treatment to older adults by translating research findings into effective strategies and interventions to improve the care of older adults and reduce patient harm. She has received funding from the National Institute on Aging, the Claude D. Pepper Older American Independence Centers, the University of Michigan Biology of Cardiovascular Aging Core and the Elizabeth Caroline Crosby Research Award. She currently also serves at the ATA's Board of Directors and as Co-Chair of the ATA's Hypothyroidism Guidelines Task Force . She has served as Co-Chair for the ATA’s Annual Program Committee (2021-2022), Chair of the ATA’s Women in Thyroidology (2022-2023) and Chair for AACE's Thyroid Disease State Network (2023-2024). She is an Associate Editor for Endocrine Practice, and serves on the Editorial Board for Thyroid. In recognition of her accomplishments she has received the 2026 Woman of the Year Award from the ATA, the 2021 Young Physician Scientist Award from the American Society for Clinical Investigation, the 2021 Rising Star in Endocrinology from AACE and the 2020 Women Advancing Thyroid Research Award from the ATA.
Links
https://scholar.google.com/citations?user=KTIy7mMAAAAJ&hl=en https://www.uofmhealth.org/profile/3187/maria-papaleontiou-md
Qualifications
-
Metabolism, Endocrinology and Diabetes FellowshipUniversity of Michigan, Internal Medicine, Ann Arbor, United States
2011 - 2013
Other
-
Metabolism, Endocrinology and Diabetes Fellowship (Chief Fellow)University of Michigan, Internal Medicine, Ann Arbor, United States
2012 - 2013
Other
-
Internal Medicine ResidencySaint Peter's University Hospital, New Brunswick, United States
2008 - 2011
Residency
-
Mini-MBARutgers University, New Brunswick, United States
2010 - 2010
Other
-
Certificate in Clnical Research Organization and ManagementDrexel College of Medicine, Philadelphia, United States
2009 - 2010
Other
-
MDFirst Faculty of Medicine, Charles University, Katerinska 32 121 08 Praha 2, Prague, Czech Republic
1998 - 2004
-
BAMacalester College, St. Paul, MN, United States
1994 - 1998
Center Memberships
-
Center MemberSamuel and Jean Frankel Cardiovascular Center
-
Center MemberInstitute for Healthcare Policy and Innovation
-
Center MemberAI and Digital Health Innovation
-
Center MemberRogel Cancer Center
Research Overview
1. Undertreatment/Overtreatment of benign thyroid disorders and thyroid cancer in older adults
2. Skeletal and cardiovascular effects of iatrogenic thyrotoxicosis
3. The impact of age and comorbidity on thyroid cancer decision making
4. Reducing low-value care in older adults with thyroid disease
5. Deprescribing
Recent Publications
-
Papaleontiou M. 2026 May 1;PresentationConsiderations in the Diagnosis and Management of Subclinical Thyroid Disease in Older Adults
-
Papaleontiou M. 2026 May 1;PresentationRethinking Hypothyroidism: Role of T3 and T4 combination therapy
-
McManus C, Douek ML, Dream SY, Graves CE, Schmeltz LR, Sinclair C, Stan M, Papaleontiou M. Endocr Pract, 2026 Jul 4;Journal ArticleThe Use of Directed Ablative Techniques for Autonomously Functioning Thyroid Nodules: A Statement from the North American Society for Interventional Thyroidology.
DOI:10.1016/j.eprac.2026.05.039 PMID: 42401203 -
Sinha S, Watamabe M, Spencer-Segal J, Haymart M, Papaleontiou M. 2026 Jun 13;Proceeding / Abstract / PosterDiscordance between clinical guideline recommendations and testosterone prescribing in a real-world setting.
-
2026 Jun 8;PresentationOral Abstract Session, Thyroid Hormone in Pregnancy and in the Developing Brain
-
Singh Ospina N, Papaleontiou M. Endocrine Practice, 2026 Jun 8; S1530-891X(26)01018-9.:Journal ArticleAdvancements and Insights in Thyroid Health.
-
Turcu AF, Salman Z, Kromm SM, Zhang L, Zhao L, Suzer-Gurtekin ZT, Vincent G, Papaleontiou M. J Am Heart Assoc, 2026 May 29; e049858Journal ArticleBarriers for Secondary Hypertension Screening in the United States: A National Physician Survey.
DOI:10.1161/JAHA.126.049858 PMID: 42216298 -
Papaleontiou, MD M. 2026 Feb 13;PresentationNatural History of Hypothyroidism and Thyroid Hormone Deprescribing
Featured News & Stories